JP2017510590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510590A5 JP2017510590A5 JP2016559366A JP2016559366A JP2017510590A5 JP 2017510590 A5 JP2017510590 A5 JP 2017510590A5 JP 2016559366 A JP2016559366 A JP 2016559366A JP 2016559366 A JP2016559366 A JP 2016559366A JP 2017510590 A5 JP2017510590 A5 JP 2017510590A5
- Authority
- JP
- Japan
- Prior art keywords
- spiro
- methyl
- dihydro
- triaza
- diaza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2,8-diaza-spiro [4.5] decan-1-one-yl Chemical group 0.000 claims 122
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000000066 myeloid cell Anatomy 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- AVQXDJUHGDOBKN-UHFFFAOYSA-N 1-methyl-3h-2,1-benzothiazole Chemical compound C1=CC=C2N(C)SCC2=C1 AVQXDJUHGDOBKN-UHFFFAOYSA-N 0.000 claims 1
- NYLGITXFVVEBLZ-UHFFFAOYSA-N 1-methylindazol-3-amine Chemical group C1=CC=C2N(C)N=C(N)C2=C1 NYLGITXFVVEBLZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- KZHXHOJTGTURDJ-UHFFFAOYSA-N 1h-indazol-3-ylcarbamic acid Chemical compound C1=CC=C2C(NC(=O)O)=NNC2=C1 KZHXHOJTGTURDJ-UHFFFAOYSA-N 0.000 claims 1
- UATCBIAFFSRLBH-UHFFFAOYSA-N 2-tert-butyl-3h-1,2-benzothiazole Chemical compound C1=CC=C2SN(C(C)(C)C)CC2=C1 UATCBIAFFSRLBH-UHFFFAOYSA-N 0.000 claims 1
- FPWYXHKGPQQAAG-UHFFFAOYSA-N 3-oxodecanal Chemical compound CCCCCCCC(=O)CC=O FPWYXHKGPQQAAG-UHFFFAOYSA-N 0.000 claims 1
- MPEFBGVVCCHQRA-UHFFFAOYSA-N 8-[3-chloro-5-(1-methylindazol-5-yl)pyridin-4-yl]-2,8-diazaspiro[4.5]decane-1,3-dione Chemical compound ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C=1C=C2C=NN(C2=CC1)C MPEFBGVVCCHQRA-UHFFFAOYSA-N 0.000 claims 1
- OKKQGSQYZMIETI-UHFFFAOYSA-N C(C)(C)N1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F Chemical compound C(C)(C)N1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F OKKQGSQYZMIETI-UHFFFAOYSA-N 0.000 claims 1
- OMUNPUZBDSTLJV-UHFFFAOYSA-N CN1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F Chemical compound CN1N=CC(=C1)C1=CC=C(C=C1)C=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C(F)(F)F OMUNPUZBDSTLJV-UHFFFAOYSA-N 0.000 claims 1
- VZGUYBWECPUEAQ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(N=C(N2)C)=O)CC1)C=1C=C2C=NN(C2=CC1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(N=C(N2)C)=O)CC1)C=1C=C2C=NN(C2=CC1)C VZGUYBWECPUEAQ-UHFFFAOYSA-N 0.000 claims 1
- GBYCDBFSAXCWDG-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 GBYCDBFSAXCWDG-UHFFFAOYSA-N 0.000 claims 1
- TYCOTTAYUVNCMS-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C TYCOTTAYUVNCMS-UHFFFAOYSA-N 0.000 claims 1
- SOGOUJPVOZWDFQ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C SOGOUJPVOZWDFQ-UHFFFAOYSA-N 0.000 claims 1
- ZLJBWVWHTDCWFO-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(C(NCN2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(C(NCN2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)C ZLJBWVWHTDCWFO-UHFFFAOYSA-N 0.000 claims 1
- ZHRPMMZXBYARRJ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(NS(C2)(=O)=O)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(NS(C2)(=O)=O)C=C1 ZHRPMMZXBYARRJ-UHFFFAOYSA-N 0.000 claims 1
- BNUILOFXARRTCB-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC=C2C=NN(C2=C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)C1=CC=C2C=NN(C2=C1)C BNUILOFXARRTCB-UHFFFAOYSA-N 0.000 claims 1
- KBJLGGRKCRPTBK-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC2=C(S(CC2O)(=O)=O)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC2=C(S(CC2O)(=O)=O)C=C1 KBJLGGRKCRPTBK-UHFFFAOYSA-N 0.000 claims 1
- IZIZTVUBBXGCPR-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC=C(C=C1)C=1N=C(N(C1)C)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CCNC2=O)CC1)C1=CC=C(C=C1)C=1N=C(N(C1)C)C IZIZTVUBBXGCPR-UHFFFAOYSA-N 0.000 claims 1
- ZNMSRFYDOSAZLZ-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 ZNMSRFYDOSAZLZ-UHFFFAOYSA-N 0.000 claims 1
- AOIKBYAXRMABCX-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)C(C)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)C(C)C AOIKBYAXRMABCX-UHFFFAOYSA-N 0.000 claims 1
- IRRYSPITUYJSDM-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)CC Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC2=CN(N=C2C=C1)CC IRRYSPITUYJSDM-UHFFFAOYSA-N 0.000 claims 1
- FCYOCMIKYSONQM-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CC(C)(C)O Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CC(C)(C)O FCYOCMIKYSONQM-UHFFFAOYSA-N 0.000 claims 1
- SIBZRLUQLOVPGB-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCO Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCO SIBZRLUQLOVPGB-UHFFFAOYSA-N 0.000 claims 1
- NKKSTXMWBZRFCS-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCS(=O)(=O)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C(C=C1)C=1C=NN(C1)CCS(=O)(=O)C NKKSTXMWBZRFCS-UHFFFAOYSA-N 0.000 claims 1
- MGWQJHKQHJNDKH-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C2C=NN(C2=C1)C Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C1=CC=C2C=NN(C2=C1)C MGWQJHKQHJNDKH-UHFFFAOYSA-N 0.000 claims 1
- XPWYZFKMRUWIDU-UHFFFAOYSA-N ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C1 Chemical compound ClC=1C=NC=C(C1N1CCC2(CNC(O2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C1 XPWYZFKMRUWIDU-UHFFFAOYSA-N 0.000 claims 1
- NALGKDPHSMQYFA-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(C(NC(=N2)C)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(C(NC(=N2)C)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 NALGKDPHSMQYFA-UHFFFAOYSA-N 0.000 claims 1
- ISJQYDFLDROVOP-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(C(NCC(N2)=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 ISJQYDFLDROVOP-UHFFFAOYSA-N 0.000 claims 1
- JLLOYHKVHLPRJA-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(C(NCCN2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C=1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(C(NCCN2)=O)CC1)C=1C=CC2=C(NC(O2)=O)C=1 JLLOYHKVHLPRJA-UHFFFAOYSA-N 0.000 claims 1
- KILPTFZHIBCKGZ-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 Chemical compound ClC=1C=NC=C(C=1N1CCC2(CC(NC2=O)=O)CC1)C1=CC2=C(N(S(C2)(=O)=O)C)C=C1 KILPTFZHIBCKGZ-UHFFFAOYSA-N 0.000 claims 1
- LIFXRRLDZMTTKU-UHFFFAOYSA-N ClC=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C=1C=C2CC(N(C2=CC=1)C)=O Chemical compound ClC=1C=NC=C(C=1N1CCC2(CNC(O2)=O)CC1)C=1C=C2CC(N(C2=CC=1)C)=O LIFXRRLDZMTTKU-UHFFFAOYSA-N 0.000 claims 1
- VOFNJBCAXJKFQM-UHFFFAOYSA-N NC1=NNC2=CC(=CC=C12)C=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)Cl Chemical compound NC1=NNC2=CC(=CC=C12)C=1C=NC=C(C1N1CCC2(CC(NC2=O)=O)CC1)Cl VOFNJBCAXJKFQM-UHFFFAOYSA-N 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- SXOVJOBXZPCKRA-UHFFFAOYSA-N spiro[1h-indole-3,4'-piperidine]-2-one Chemical compound O=C1NC2=CC=CC=C2C11CCNCC1 SXOVJOBXZPCKRA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001145.3 | 2014-03-27 | ||
| EP14001145 | 2014-03-27 | ||
| PCT/EP2015/000528 WO2015144290A1 (en) | 2014-03-27 | 2015-03-10 | Pyridyl piperidines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510590A JP2017510590A (ja) | 2017-04-13 |
| JP2017510590A5 true JP2017510590A5 (enExample) | 2018-04-19 |
| JP6434989B2 JP6434989B2 (ja) | 2018-12-05 |
Family
ID=50389770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559366A Expired - Fee Related JP6434989B2 (ja) | 2014-03-27 | 2015-03-10 | ピリジルピペリジン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9926319B2 (enExample) |
| EP (1) | EP3122739B1 (enExample) |
| JP (1) | JP6434989B2 (enExample) |
| CN (1) | CN106458992B (enExample) |
| AU (1) | AU2015236855B2 (enExample) |
| CA (1) | CA2943659C (enExample) |
| ES (1) | ES2720324T3 (enExample) |
| IL (1) | IL247728B (enExample) |
| WO (1) | WO2015144290A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6447304B2 (ja) * | 2015-03-27 | 2019-01-09 | Jsr株式会社 | 液晶配向剤、液晶配向膜及びその製造方法、液晶表示素子、位相差フィルム及びその製造方法、重合体並びに化合物 |
| MX2017015456A (es) | 2015-06-01 | 2018-11-29 | Bantam Pharmaceutical Llc | Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. |
| EP3370720A1 (en) * | 2015-11-03 | 2018-09-12 | Lu License AB | Compounds for treatment of hypoproliferative disorders |
| WO2018102452A2 (en) | 2016-11-30 | 2018-06-07 | Bantam Pharmaceutical, Llc | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases |
| CN118930533A (zh) * | 2016-11-30 | 2024-11-12 | 班塔姆制药有限责任公司 | 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法 |
| ES3004107T3 (en) | 2017-01-30 | 2025-03-11 | Univ Kyoto | Novel compound, and method for producing regulatory t cells |
| WO2019068613A1 (en) | 2017-10-02 | 2019-04-11 | Boehringer Ingelheim International Gmbh | NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS |
| US20220396577A1 (en) * | 2019-12-17 | 2022-12-15 | Merck Sharp & Dohme Llc | Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors |
| AU2022349176A1 (en) | 2021-09-27 | 2024-04-11 | Kyoto University | Method for producing t cell |
| TW202330911A (zh) | 2021-11-24 | 2023-08-01 | 日商雷格細胞股份有限公司 | 人類誘導性控制性ｔ細胞及其製作方法 |
| JPWO2023095802A1 (enExample) | 2021-11-24 | 2023-06-01 | ||
| CN119256076A (zh) | 2022-03-23 | 2025-01-03 | 国立大学法人京都大学 | 用于产生调节性t细胞的方法 |
| CN119948155A (zh) | 2022-09-26 | 2025-05-06 | 雷格细胞股份有限公司 | 含有嵌合抗原受体（car）的诱导性调节性t细胞 |
| JPWO2024071010A1 (enExample) | 2022-09-26 | 2024-04-04 | ||
| KR20250140618A (ko) | 2023-02-08 | 2025-09-25 | 레그셀 가부시키가이샤 | 천포창을 치료 또는 예방하기 위한 의약 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| JP5926272B2 (ja) * | 2010-11-12 | 2016-05-25 | ドイチェス クレブスフォルシュンクスツェントルム | Ｗｎｔ経路のアンタゴニストとしてのクロメン誘導体及びそれらの類似体 |
| PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| MA37577B1 (fr) * | 2012-05-04 | 2018-05-31 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques |
| EP2912037B1 (en) * | 2012-10-08 | 2018-08-22 | Merck Patent GmbH | 2-aminopyridine compounds |
-
2015
- 2015-03-10 WO PCT/EP2015/000528 patent/WO2015144290A1/en not_active Ceased
- 2015-03-10 EP EP15709097.8A patent/EP3122739B1/en not_active Not-in-force
- 2015-03-10 US US15/129,338 patent/US9926319B2/en active Active
- 2015-03-10 CN CN201580027519.1A patent/CN106458992B/zh not_active Expired - Fee Related
- 2015-03-10 CA CA2943659A patent/CA2943659C/en active Active
- 2015-03-10 JP JP2016559366A patent/JP6434989B2/ja not_active Expired - Fee Related
- 2015-03-10 AU AU2015236855A patent/AU2015236855B2/en not_active Ceased
- 2015-03-10 ES ES15709097T patent/ES2720324T3/es active Active
-
2016
- 2016-09-08 IL IL247728A patent/IL247728B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510590A5 (enExample) | ||
| TWI879728B (zh) | Shp2磷酸酶抑制劑及其使用方法 | |
| JP2016500694A5 (enExample) | ||
| EP3630770B1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| JP6631616B2 (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| DE60208792T2 (de) | Tyrosin-kinase inhibitoren | |
| KR102485100B1 (ko) | 치환된 우레아 유도체 및 이의 약제학적 용도 | |
| EP2953940B1 (en) | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists | |
| EP4010335A1 (en) | Shp2 inhibitors | |
| BR112019018991A2 (pt) | compostos e composições para tratar distúrbios hematológicos | |
| JP2013539777A5 (enExample) | ||
| AU1091301A (en) | Tyrosine kinase inhibitors | |
| JP2019508384A (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| JP2010513495A (ja) | 新規なｊｎｋ阻害剤 | |
| WO2003009852A1 (en) | Tyrosine kinase inhibitors | |
| JP2010535201A (ja) | 抗癌治療としての抗有糸分裂薬およびオーロラキナーゼ阻害薬 | |
| KR20150120383A (ko) | 신규 피라졸 유도체 | |
| KR20160056896A (ko) | Ｐｉｍ 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물 | |
| AU2013243020A1 (en) | Cyclic amides as MetAP-2 inhibitors | |
| KR20230107419A (ko) | 암 치료 방법 | |
| EP2651939A1 (en) | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | |
| AU2011344001A1 (en) | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | |
| WO2014151936A9 (en) | Octahydropyrrolopyrroles, their preparation and use | |
| WO2013117645A1 (en) | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases | |
| CN104513257B (zh) | 取代脲衍生物及其在药物中的应用 |